Recent Updates
Recently added Catalysts
GOSS Positive Sentiment

Seralutinib targets fibrotic pathways in IPF: Evidence from single-cell transcriptomics

Thursday, January 29, 2026 BiopharmaWatch Research 2 min read
Add on Google
Key Takeaway: The article discusses Seralutinib's targeting of fibrotic pathways in idiopathic pulmonary fibrosis (IPF), supported by evidence from single-cell transcriptomics. This research highlights the drug's potential to improve treatment outcomes for patients with pulmonary diseases. The findings suggest a promising avenue for further investigation and development in this therapeutic area.
Price reaction · baseline $2.55 (2026-01-28 close) · hit pre-market · 2 other GOSS headline(s) in the window, move may be shared
day 0 close
-5.1%
day 1 · peak
-10.6%
day 3
+4.7%

Market Sentiment Analysis

POSITIVE FACTORS

  • Seralutinib effectively targets fibrotic pathways in IPF.
  • Evidence from single-cell transcriptomics supports its efficacy.
  • Potential for improved treatment options in pulmonary diseases.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+53%
120-day peak, hindsight
Typical move
5.9%
average across 2 past catalysts
Cash runway
~4 mo
High dilution risk
Lead asset
GB001
Phase 2 · Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)

Full Press Release Details

Seralutinib targets fibrotic pathways in IPF: Evidence from single-cell transcriptomics
• About Overview Team Management Board of Directors Collaboration Contact Locations Contact Form Sponsorship Disclosure
• Seralutinib About Seralutinib PAH PH-ILD Posters & Presentations
• Patients Overview Expanded Access
• Investors Overview News Events & Presentations Events Presentations Filings Governance Overview Committee Composition Management Board of Directors Stock Stock Quote & Chart Historical Price Lookup Investment Calculator Analyst Coverage Info FAQs Contact IR Email Alerts
• Careers & Culture Who We Are Open Positions
• Overview
• Team
• Management
• Board of Directors
• Collaboration
• Contact
• Locations
• Contact Form
• Sponsorship Disclosure
• About Seralutinib
• PAH
• PH-ILD
• Posters & Presentations
• Overview
• Expanded Access
• Overview
• News
• Events & Presentations Events Presentations
• Filings
• Governance Overview Committee Composition Management Board of Directors
• Stock Stock Quote & Chart Historical Price Lookup Investment Calculator Analyst Coverage
• Info FAQs Contact IR Email Alerts
• Events
• Presentations
• Overview
• Committee Composition
• Management
• Board of Directors
• Stock Quote & Chart
• Historical Price Lookup
• Investment Calculator
• Analyst Coverage
• FAQs
• Contact IR
• Email Alerts
• Who We Are
• Open Positions

Frequently Asked Questions

What is Seralutinib used for?

Seralutinib is used to target fibrotic pathways in idiopathic pulmonary fibrosis (IPF).

What evidence supports Seralutinib's efficacy?

Evidence from single-cell transcriptomics supports the efficacy of Seralutinib in treating IPF.

How does Seralutinib affect pulmonary diseases?

Seralutinib has the potential to improve treatment outcomes for patients with pulmonary diseases.

ShareAdd on Google
Tags: GOSS Viatris Investor Conferences Healthcare Seralutinib IPF fibrotic pathways single-cell transcriptomics pulmonary diseases
Last updated: Jan 29, 2026

Biotech snapshot

Cash runway
$57M liquidity · $13M/mo burn
~4 mo
High dilution risk
Lead asset
GB001Phase 2
Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP) →

Catalyst track record

+53%
best trade around GOSS's most recent catalyst

Peak hindsight return over a 120-day window, across 2 tracked FDA/PDUFA catalysts for GOSS.

See every catalyst's timing & PoA →